Zepp Health (ZEPPN) Stock Forecast & Price Target
ZEPPN Analyst Ratings
ZEPPN Stock 12 Month Forecast
Average Price Target
MXN 823.96▲(224.39% Upside)Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Siddharth Rajeev | Fundamental Research | MXN 995.85→MXN 823.96 | buy | 224.39%Upside | Reiterated | 10/06/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Siddharth Rajeev | 10/06/26 | MXN 995.85→MXN 823.96 | buy | 224.39%Upside | Reiterated | Fundamental Research |
Best Analysts Covering Zepp Health
Copying Siddharth Rajeev's trades and holding each position for 3 Months would result in 27.27% of your transactions generating a profit, with an average return of +46.75% per trade.
Copying Siddharth Rajeev's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of +74.25% per trade.
Copying Siddharth Rajeev's trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of +41.53% per trade.
ZEPPN Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 1 | 1 | 1 |
In the current month, ZEPPN has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZEPPN average Analyst price target in the past 3 months is 823.96.
ZEPPN Financial Forecast
ZEPPN Earnings Forecast
Next quarter’s earnings estimate for ZEPPN is -MXN 0.94 with a range of ― to ―. The previous quarter’s EPS was -MXN 0.94. Its overall industry beat the EPS estimate 49.22% of the time in the past 12 months.
ZEPPN Sales Forecast
Next quarter’s sales forecast for ZEPPN is MXN 1.20B with a range of ― to ―. The previous quarter’s sales results were MXN 1.20B. Its overall industry beat sales estimates 53.85% of the time in the past 12 months.